Michael Gibbons - Concepedia

Author

Michael Gibbons

Royal Devon & Exeter NHS Foundation Trust ORCID

Also Known As

Alex Berry, Amber Ford, Gibbons, M, J Blaikley, J George, J. George, J.R. Geddes, L Price, M A Gibbons, M Gibbons

160

Publications

5.2K

Citations

H-Index

Concepts

All Affiliations

Royal Devon & Exeter NHS Foundation Trust University of Edinburgh University of Exeter Imperial College London North Bristol NHS Trust

About

Michael Gibbons is an author at Royal Devon & Exeter NHS Foundation Trust specializing in medicine, pulmonary disease, and pulmonary fibrosis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	720
2	Epidemiology	2	2	228
3	Public Health	1	1	12
4	Emergency Medicine	1	1	12
5	Gastroenterology	1	1	168

Michael Gibbons

Publications

3.5K

Citations

H-Index

Page 1

	Year	Citations
Regulation of Transforming Growth Factor-β1–driven Lung Fibrosis by Galectin-3 Alison C. MacKinnon, Michael Gibbons, Sarah L. Farnworth, American Journal of Respiratory and Critical Care Medicine	2011	508
Ly6C <sup>hi</sup> Monocytes Direct Alternatively Activated Profibrotic Macrophage Regulation of Lung Fibrosis Michael Gibbons, Alison C. MacKinnon, Prakash Ramachandran, American Journal of Respiratory and Critical Care Medicine	2011	462
Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study Rachael A Evans, Olivia C. Leavy, Matthew Richardson, The Lancet Respiratory Medicine	2022	407
Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial Janusz Jankowski, John de Caestecker, Sharon Love, The Lancet	2018	259
Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial Toby M. Maher, Veronica A Tudor, Peter Saunders, The Lancet Respiratory Medicine	2022	245
Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study Thomas M Drake, Annemarie B Docherty, Ewen M. Harrison, American Journal of Respiratory and Critical Care Medicine	2020	228
Telomere length and risk of idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease: a mendelian randomisation study Anna Duckworth, Michael Gibbons, Richard J. Allen, The Lancet Respiratory Medicine EpidemiologyAdvanced Lung DiseaseIdiopathic Pulmonary FibrosisTelomere LengthPathology	2020	216
Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis Nikhil Hirani, Alison C. MacKinnon, Lisa Nicol, European Respiratory Journal	2020	205
Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study Joshua J. Solomon, Sonye K. Danoff, Felix Woodhead, The Lancet Respiratory Medicine Rheumatoid DisorderRheumatologyPharmacologyClinical TrialsPulmonary Pharmacology	2022	182
Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus Zhan Su, Laura J. Gay, Amy Strange, Nature Genetics EsophagusEsophageal CancerGenetic DisorderGeneticsGenetic Epidemiology	2012	168

Page 1